SOMAGEN AQUA

SOMAGEN AQUA  90 IU / PEN -30 MG / 3 ML

• Product Type: Human Growth Hormone (HGH)

• Active Ingredient: Somatropin

• Concentration: 32 IU (10.6 mg) per vial

• Volume: 90 IU PPEN 30 MG / 3 ML PEN

• Description:
• SOMAGEN AQUA  90 IU / PEN -30 MG / 3 ML PENC is a high-quality human growth hormone formulation designed to support muscle growth, enhance recovery, and promote overall well-being. Each kit contains  90 IU / PEN -30 MG / 3 ML PEN of Somatropin, a recombinant form of HGH identical to the naturally occurring hormone in the human body. This potent formulation is ideal for athletes and bodybuilders looking to achieve significant gains in muscle mass, reduce body fat, and improve physical performance.

• Product Features:
• Potency: 90 IU / PEN -30 MG / 3 ML PEN
• Presentation: 90 IU / PEN -30 MG / 3 ML PEN providing a comprehensive supply for research purposes
• Composition: High-purity Somatropin ensuring optimal efficacy and consistency
• Half-Life: Approximately 2-3 hours, requiring frequent administration for sustained effects
• Detection Time: Typically detectable for up to several weeks, suitable for long-term studies
• Key Benefits:
• Enhanced Muscle Growth: Promotes significant muscle development and strength gains.
• Improved Recovery: Accelerates recovery times, allowing for more frequent and intense workouts.
• Fat Loss: Aids in reducing body fat, contributing to a leaner physique.
• Overall Well-being: Supports better sleep quality, skin elasticity, and metabolic function.
• The dosage and frequency of administration should be determined based on the specific requirements of the study. It is crucial to handle the product with care and follow all applicable safety guidelines during research.

• Side Effects:
• Potential side effects include joint pain, swelling, and increased risk of diabetes and cardiovascular issues. Regular monitoring and appropriate adjustments can help manage these risks.

• Contraindications:
• SOMAGEN AQUA  90 IU / PEN -30 MG / 3 ML PEN should not be used by individuals with active cancer, proliferative retinopathy, or hypersensitivity to any component of the product. Always consult with a healthcare provider before use in research.